Crombie Jennifer, Davids Matthew S
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Am J Hematol. 2017 Dec;92(12):1393-1397. doi: 10.1002/ajh.24808. Epub 2017 Jul 29.
As the therapeutic landscape for chronic lymphocytic leukemia (CLL) continues to expand, biological predictors of response to therapy are becoming increasingly important. One such predictive biomarker is the mutational status of the variable region of the immunoglobulin heavy chain (IGHV) gene, which is a powerful predictor of duration of response and overall survival with chemoimmunotherapy (CIT). As this test may influence choice of therapy between CIT and novel agents, it is critical that providers understand how mutational status is determined and the limitations of testing. Here, we describe the details of IGHV mutational status testing, highlighting the appropriate way to interpret this information and best apply it to the care of patients with CLL.
随着慢性淋巴细胞白血病（CLL）的治疗前景不断拓展，治疗反应的生物学预测指标变得愈发重要。其中一个预测生物标志物是免疫球蛋白重链（IGHV）基因可变区的突变状态，它是化疗免疫疗法（CIT）反应持续时间和总生存期的有力预测指标。由于该检测可能会影响CIT与新型药物之间的治疗选择，因此医疗服务提供者了解突变状态如何确定以及检测的局限性至关重要。在此，我们描述IGHV突变状态检测的详细情况，强调解读该信息的恰当方式以及将其最佳应用于CLL患者护理的方法。
